Editor’s Note: The story has been updated with comments from J&J The National Institutes of Health (NIH) on Tuesday ...

Patients with atrial fibrillation receiving the factor XI inhibitor abelacimab have a lower risk for bleeding than those ...

Perugia, Italy - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) have been ...

BOSTON, MA—For patients undergoing transradial coronary procedures, a short course of rivaroxaban (Xarelto; Bayer/Janssen) reduces the rate of radial artery occlusion without significantly increasing ...

LAS VEGAS, NV—The first day of VIVA 2017 began with some timely insights into pharmacotherapy with non-vitamin K oral anticoagulants (NOACs) in patients with deep vein thrombosis (DVT), and a look ...

Akums Drugs & Pharmaceuticals Ltd. has received its first product approval from the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) for Rivaroxaban, ...

Please provide your email address to receive an email when new articles are posted on . “The mortality benefit demonstrated in the COMPASS trial ... is externally consistent with prior evidence of a ...

An anti-stroke drug touted as more effective than older blood thinners may be riskier than doctors and patients have been led to believe. Data has shown that the drug rivaroxaban may be significantly ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The main clinical effectiveness evidence ...